MONTREAL, QUEBEC -- (MARKET WIRE) -- September 27, 2006 -- Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today that it will be presenting a poster on in vitro and in vivo metabolism of its lead HIV protease inhibitor (PI), PPL-100, a prodrug of PL-100, at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in San Francisco, September 27-30 2006. The poster entitled “PL-100, a Next Generation Protease Inhibitor Against Drug-Resistant HIV: In Vitro and In Vivo metabolism” will be presented during the poster session HIV: New Antiretroviral Agents, to be held on Wednesday, September 27, from 1:30 p.m. to 3:00 p.m.
